Replies to post #77367 on $heff's $tation of $tocks & $olid DD

[pmony5]

ADMP agreed at 63 million $$ market cap & deep pipeline seems crazy cheap here & only 1 way to go GLTY & make $$$$$$$$ BTW 95 Billion dollar 3M as partner makes me feel so good waiting this one out

[pharma_trader]

ADMP $6.50 solid DD--LINK BACK:

ADMP- Solid DD and Link Back--Adamis Pharmaceuticals. Recently uplisted to NASDAQ. Market cap $62M

ADMP -> CRT capital group initiated with buy recently and $15 PT REPORT and some of the catalyst reported are here:

Some key points from report: "Having recently acquired the exclusive rights to 3M’s multi-dose dry powder inhaler (DPI),we believe there is the potential for Adamis to develop a competing product to GSK’s Advair Diskus by 2017."

* " In addition, the Company plans on filing an epinephrine pre-filled syringe (forthe treatment of anaphylaxis) product by Q1’14, which could be commercialized by year end."

• In Q1 2014, Adamis plans on filing its epinephrine pre-filled syringe to the FDA via the 505(b)(2) pathway. The Company expects to hear back on an approval decision by late 2014/early 2015. Adamis is partnered with Catalent, who is the contract manufacturer.

• By mid-2014, Adamis plans to conduct a small, 80-patient study with its Taper Dry owder Inhaler (DPI) for treatment of COPD/asthma. We believe the main purpose of

this trial will be to demonstrate the comparable efficacy profile of its recently acquired inhaler vs. GSK’s Advair (the “gold standard” product in the market). We believe this trial could be completed by Q4’14. Adamis will be supplied the product by 3M.

• By mid’14, we believe Adamis will look to meet with the FDA to discuss its development plans on APC-1000 (beclomethasone inhaler - comparable to TEVA’s QVAR). We believe Adamis has plans to run a Phase 3 study evaluating the efficacy of its product vs. Qvar. On this product, Adamis is partnered with Beximco.

• By late 2014, we believe Adamis could secure additional partners for its Taper Dry Powder Inhaler for international markets. We would not rule out Adamis also looking for potential partners for its APC-1000 beclomethasone product.

Full report can be found here: https://docs.google.com/file/d/0Bwgu6jYVrAKiZDVfRWpPZ2E4b0hOc2p0LUZ5MlA4OFFxM0xj/edit?pli=1